90 likes | 97 Views
Explore the role of PDGF Receptor Beta in Chronic Myelomonocytic Leukemia, its impact on blood cell lineage, translocations, and responsiveness to treatment. Learn about ETV6/PDGFRB transgenes and PDGFRB null mutants. Discover the implications for kidney development and hematological disorders.
E N D
PDGFR-B is a receptor tyrosine kinase and is distinct from PDGFR-A
PDGF signaling activates a number of key pathways in the cell
PDGFRB null mutants showed abnormal kidney development and hematological disorders Nucleated and fragmented red blood cells
ETV6/PDGFRB trangenes can lead to Chronic Myelomonocytic Leukemia Blood Cell Lineage:
A variety of PDGFRB translocations are involved in myeloproliferative disorders
ETV6/PDGFRB transgene leads to constitutive activation of PDGFRB kinase activity
Many patients with PDFGRB rearrangements are highly responsive to imatinib (Gleevec) treatment
References • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC556485/pdf/emboj00087-0168.pdf • http://ac.els-cdn.com/0092867494903220/1-s2.0-0092867494903220-main.pdf?_tid=1cd20a74-2057-11e7-bb6d-00000aacb360&acdnat=1492094597_218fbe98c44994d126c93fd1f370963a • https://www.ncbi.nlm.nih.gov/pubmed/22578774 • https://www.cancer.org/cancer/chronic-myelomonocytic-leukemia/detection-diagnosis-staging.html • https://www.lls.org/leukemia/chronic-myelomonocytic-leukemia • http://www.haematologica.org/content/92/2/145 • https://www.ncbi.nlm.nih.gov/gtr/conditions/C1851585/ • http://www.nejm.org/doi/full/10.1056/NEJMoa020150